What is BioInVision?
BioInVision operates at the intersection of advanced computational intelligence and biological research, providing specialized imaging solutions that cater to both pre-clinical and clinical environments. The company's proprietary technology, anchored by its flagship CryoViz and IschemiaViz platforms, utilizes sophisticated AI-driven algorithms to deliver high-fidelity analysis for complex medical applications. By focusing on critical areas such as cardiovascular disease diagnosis, stem cell research, and oncology, BioInVision serves a diverse clientele of cardiologists and academic researchers. Beyond hardware and software development, the firm offers a comprehensive service model, allowing external laboratories to outsource sample analysis, thereby streamlining the research workflow and enhancing the precision of molecular imaging outcomes.
How much funding has BioInVision raised?
BioInVision has raised a total of $67K across 1 funding round:
Debt
$67K
Debt (2021): $67K with participation from PPP
Key Investors in BioInVision
PPP
Public-Private Partnership
What's next for BioInVision?
With the recent infusion of capital, BioInVision is poised to scale its market presence and deepen its R&D capabilities. The strategic focus will likely shift toward expanding the clinical utility of its AI-driven diagnostic tools and enhancing the throughput of its centralized imaging service centers. As the biotech industry continues to demand higher resolution and more actionable data, BioInVision's ability to integrate its patented technology into broader clinical workflows will be a key determinant of its long-term growth. The company is expected to prioritize the commercialization of its existing product suite while exploring new frontiers in cellular imaging, ensuring it remains a critical partner for researchers and clinicians navigating the complexities of modern molecular medicine.
See full BioInVision company page
